Didn't know where to start or finish this one so I'll just throw it out there for your comments.

On the Zenith Epigenetics board KBC referred to an article about a CVR deal with BMS that ended up in court. The fiercepharma.com article that came after the article reffered to by KBC pretty much confirmed what I have been saying about BP dragging their feet about doing a deal with RVX as a result of all of the benefits that apabetalone has to offer. Here is the link to the article KBC was referring to  https://www.fiercepharma.com/pharma/bristol-myers-loses-bid-toss-64-billion-cvr-lawsuit-tied-celgene-takeover-breyanzi-approval  The article I'm talking about came right after the BMS article.

The article I'm reffering to is titled AACR: AstraZeneca offers first look at Imfinzi. The sentenc in the artcle that hit the nail on the head says "sales prospects for the anti-PD-1/L1 class could take a hit because it would mean patients need shorter treatment periods for positive outcomes" You can imagine the hit a BP would take by bringing a drug like apabetalone to the market that could have a positive effect on 20 some odd ailments.

That is the first time I have seen a statement in another article that confirms my thoughts so there you have it.

With this in mind, Eversana could be sitting on a gold mine and Resverlogix could still be a mega blockbuster at some point in the future. Whether we will still be here at that point is yet another question.

Looking forward to your comments.

tada